{"groups":[{"description":"Participants were randomized to sabatolimab plus Azacitidine","id":"FG000","title":"Sabatolimab (MBG453) + Azacitidine"},{"description":"Participants were randomized to placebo plus Azacitidine","id":"FG001","title":"Placebo + Azacitidine"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"111"},{"groupId":"FG001","numSubjects":"92"}],"type":"Progressive Disease"},{"reasons":[{"groupId":"FG000","numSubjects":"41"},{"groupId":"FG001","numSubjects":"43"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"26"},{"groupId":"FG001","numSubjects":"35"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"22"},{"groupId":"FG001","numSubjects":"22"}],"type":"Hematopoietic Stem-Cell Transplantation (HSCT) Planned"},{"reasons":[{"groupId":"FG000","numSubjects":"22"},{"groupId":"FG001","numSubjects":"27"}],"type":"Study Terminated by Sponsor"},{"reasons":[{"groupId":"FG000","numSubjects":"22"},{"groupId":"FG001","numSubjects":"28"}],"type":"Participant Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"9"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"4"}],"type":"New Therapy for Study Indication"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"4"}],"type":"Protocol Deviation"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Guardian Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}],"type":"Participants Not Treated"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"265"},{"groupId":"FG001","numSubjects":"265"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"264"},{"groupId":"FG001","numSubjects":"264"}],"type":"Participants Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}],"type":"Participants Not treated"},{"achievements":[{"groupId":"FG000","numSubjects":"264"},{"groupId":"FG001","numSubjects":"264"}],"type":"Discontinued from treatment"},{"achievements":[{"groupId":"FG000","numSubjects":"68"},{"groupId":"FG001","numSubjects":"71"}],"type":"Entered post-treatment"},{"achievements":[{"groupId":"FG000","numSubjects":"196"},{"groupId":"FG001","numSubjects":"193"}],"type":"Did not enter post-treatment"},{"achievements":[{"groupId":"FG000","numSubjects":"265"},{"groupId":"FG001","numSubjects":"265"}],"type":"Discontinued from study"},{"achievements":[{"groupId":"FG000","numSubjects":"265"},{"groupId":"FG001","numSubjects":"265"}],"type":"Full Analysis See (FAS)"},{"achievements":[{"groupId":"FG000","numSubjects":"263"},{"groupId":"FG001","numSubjects":"265"}],"comment":"Two participants (one per arm) did not receive treatment and were excluded from the Safety Set. One sabatolimab-assigned participant withdrew consent pre-treatment. Another, randomized to placebo, progressed to AML before treatment and died. One sabatolimab-assigned participant progressed to AML, received only azacitidine, and was analyzed in the placebo Safety Set.","type":"Safety Set"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"comment":"Completed = Completed treatment","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"265"},{"groupId":"FG001","numSubjects":"265"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"This study randomized participants in 149 centers in 36 participating countries."}